Patient characteristics of all allogeneic HCT recipients
| Variable . | Category . | Total (N = 946) . | P* . |
|---|---|---|---|
| Age at transplant, y | Median (IQR) | 53.3 (39.8-62.1) | .489 |
| 18-60 | 656 (69%) | .307 | |
| ≥60 | 290 (31%) | ||
| Last positive days before transplant | Median (range) | −25 (–90 to −1) | |
| Median (IQR) | −25 (–42 to −15) | ||
| Mean ± SD | −29.8 ± 20.8 | ||
| Cell source | BM | 99 (10%) | .223 |
| PBSC | 735 (78%) | ||
| CORD | 112 (12%) | ||
| Recipient CMV serostatus | Negative | 375 (40%) | .152 |
| Positive | 551 (58%) | ||
| Missing | 20 (2%) | ||
| Conditioning regimen | MA + TBI | 350 (37%) | .674 |
| MA + non-TBI | 321 (34%) | ||
| Non-MA | 275 (29%) | ||
| Donor relationship | Unrelated | 647 (68%) | .594 |
| Related | 299 (32%) | ||
| Underlying disease risk | Low | 628 (66%) | .01 |
| Intermediate | 99 (10%) | ||
| High | 219 (23%) | ||
| Pretransplant lymphocyte counts, mm3 | <100 | 109 (12%) | .415 |
| 100-300 | 73 (8%) | ||
| >300 | 762 (81%) | ||
| Missing | 2 (<1%) | ||
| Race | Non-White | 56 (6%) | .735 |
| White | 711 (75%) | ||
| Unknown | 179 (19%) | ||
| Sex | Female | 401 (42%) | .183 |
| Male | 545 (58%) | ||
| Symptoms at time of transplant | Negative | 227 (24%) | <.001 |
| No data | 19 (2%) | ||
| Asymptomatic | 114 (12%) | ||
| Symptomatic | 22 (2%) | ||
| Not tested | 564 (60%) | ||
| T-cell depletion | No | 880 (93%) | .866 |
| Yes | 66 (7%) | ||
| Pretransplant virus infection | No, not tested | 564 (60%) | <.001 |
| Negative | 227 (24%) | ||
| Positive | 155 (16%) | ||
| Virus types | Negative | 227 (24%) | <.001 |
| FLU, RSV, ADV, or HMPV† | 30 (3%) | ||
| PIV 1-4 | 23 (2%) | ||
| HRV | 80 (8%) | ||
| HCoV | 22 (2%) | ||
| Not tested | 564 (60%) | ||
| Pretransplant LRD classification | Negative | 227 (24%) | <.001 |
| Upper | 116 (12%) | ||
| Possible | 30 (3%) | ||
| Probable | 1 (<1%) | ||
| Proven | 8 (1%) | ||
| Not tested | 564 (60%) | ||
| Virus type/location/symptom composite | Negative or not tested (combined) | 791 (84%) | <.001 |
| HRV: URI asymptomatic or no data | 45 (5%) | ||
| HRV: URI symptomatic | 20 (2%) | ||
| HRV: LRD (possible with symptoms, proven, probable) | 15 (2%) | ||
| All other viruses: URI asymptomatic or no data | 46 (5%) | ||
| All other viruses: URI symptomatic | 5 (1%) | ||
| All other viruses: LRD | 24 (3%) | ||
| HCT-CI score | 0 | 196 (21%) | <.001 |
| 1-2 | 318 (34%) | ||
| ≥3 | 432 (46%) |
| Variable . | Category . | Total (N = 946) . | P* . |
|---|---|---|---|
| Age at transplant, y | Median (IQR) | 53.3 (39.8-62.1) | .489 |
| 18-60 | 656 (69%) | .307 | |
| ≥60 | 290 (31%) | ||
| Last positive days before transplant | Median (range) | −25 (–90 to −1) | |
| Median (IQR) | −25 (–42 to −15) | ||
| Mean ± SD | −29.8 ± 20.8 | ||
| Cell source | BM | 99 (10%) | .223 |
| PBSC | 735 (78%) | ||
| CORD | 112 (12%) | ||
| Recipient CMV serostatus | Negative | 375 (40%) | .152 |
| Positive | 551 (58%) | ||
| Missing | 20 (2%) | ||
| Conditioning regimen | MA + TBI | 350 (37%) | .674 |
| MA + non-TBI | 321 (34%) | ||
| Non-MA | 275 (29%) | ||
| Donor relationship | Unrelated | 647 (68%) | .594 |
| Related | 299 (32%) | ||
| Underlying disease risk | Low | 628 (66%) | .01 |
| Intermediate | 99 (10%) | ||
| High | 219 (23%) | ||
| Pretransplant lymphocyte counts, mm3 | <100 | 109 (12%) | .415 |
| 100-300 | 73 (8%) | ||
| >300 | 762 (81%) | ||
| Missing | 2 (<1%) | ||
| Race | Non-White | 56 (6%) | .735 |
| White | 711 (75%) | ||
| Unknown | 179 (19%) | ||
| Sex | Female | 401 (42%) | .183 |
| Male | 545 (58%) | ||
| Symptoms at time of transplant | Negative | 227 (24%) | <.001 |
| No data | 19 (2%) | ||
| Asymptomatic | 114 (12%) | ||
| Symptomatic | 22 (2%) | ||
| Not tested | 564 (60%) | ||
| T-cell depletion | No | 880 (93%) | .866 |
| Yes | 66 (7%) | ||
| Pretransplant virus infection | No, not tested | 564 (60%) | <.001 |
| Negative | 227 (24%) | ||
| Positive | 155 (16%) | ||
| Virus types | Negative | 227 (24%) | <.001 |
| FLU, RSV, ADV, or HMPV† | 30 (3%) | ||
| PIV 1-4 | 23 (2%) | ||
| HRV | 80 (8%) | ||
| HCoV | 22 (2%) | ||
| Not tested | 564 (60%) | ||
| Pretransplant LRD classification | Negative | 227 (24%) | <.001 |
| Upper | 116 (12%) | ||
| Possible | 30 (3%) | ||
| Probable | 1 (<1%) | ||
| Proven | 8 (1%) | ||
| Not tested | 564 (60%) | ||
| Virus type/location/symptom composite | Negative or not tested (combined) | 791 (84%) | <.001 |
| HRV: URI asymptomatic or no data | 45 (5%) | ||
| HRV: URI symptomatic | 20 (2%) | ||
| HRV: LRD (possible with symptoms, proven, probable) | 15 (2%) | ||
| All other viruses: URI asymptomatic or no data | 46 (5%) | ||
| All other viruses: URI symptomatic | 5 (1%) | ||
| All other viruses: LRD | 24 (3%) | ||
| HCT-CI score | 0 | 196 (21%) | <.001 |
| 1-2 | 318 (34%) | ||
| ≥3 | 432 (46%) |
AdV, human adenovirus; BM, bone marrow; CMV, cytomegalovirus; CORD, umbilical cord blood; IQR, interquartile range; MA, myeloablative; PBSC, peripheral blood stem cell; TBI, total body irradiation.
Fisher’s exact or χ2 test was used for comparisons for categorical variables, and Wilcoxon rank sum test was used for continuous variables, as appropriate.
FLU (n = 8), RSV (n = 10), ADV (n = 1), and HMPV (n = 11).